Fingerprint
Dive into the research topics of 'Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis
Sergio M. Borgia*, Janet Dearden, Eric M. Yoshida, Stephen D. Shafran, Ashley Brown, Ziv Ben-Ari, Matthew E. Cramp, Curtis Cooper, Matthew Foxton, Conrado Fernandez Rodriguez, Rafael Esteban, Robert Hyland, Sophia Lu, Brian J. Kirby, Amy Meng, Svetlana Markova, Hadas Dvory-Sobol, Anu O. Osinusi, Rafael Bruck, Javier Ampuero
*Corresponding author for this work
- McMaster University
- Barts Health NHS Trust
- Vancouver Coastal Health
- University of Alberta
- Imperial College Healthcare NHS Trust
- Sheba Medical Center at Tel Hashomer
- University of Ottawa
- Chelsea and Westminster Hospital NHS Foundation Trust
- Fundacion Hospital Alcorcon
- Autonomous University of Barcelona
- Gilead Sciences, Inc.
- Tel Aviv Sourasky Medical Center
- Hospital Universitario Virgen del Rocio
- Nottingham University Hospitals NHS Trust
- King's College Hospital NHS Foundation Trust
- NHS Greater Glasgow and Clyde
- Royal Adelaide Hospital
- Hamilton Health Sciences
- University of Montreal
- Shaare Zedek Medical Center
- Universidad Autónoma de Madrid
- Auckland District Health Board
Research output: Contribution to journal › Article › peer-review
10
Downloads
(Pure)